These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38001504)

  • 1. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis.
    Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
    Arthritis Res Ther; 2023 Nov; 25(1):226. PubMed ID: 38001504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Value of
    Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
    J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of
    Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis.
    Enevold C; Baslund B; Linde L; Josephsen NL; Tarp U; Lindegaard H; Jacobsen S; Nielsen CH
    Pharmacogenet Genomics; 2014 Aug; 24(8):401-5. PubMed ID: 24978393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.
    Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Ángel Calleja-Hernández M
    Pharmacogenomics J; 2018 Jan; 18(1):167-172. PubMed ID: 27958380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.
    Luxembourger C; Ruyssen-Witrand A; Ladhari C; Rittore C; Degboe Y; Maillefert JF; Gaudin P; Marotte H; Wendling D; Jorgensen C; Cantagrel A; Constantin A; Nigon D; Touitou I; Gottenberg JE; Pers YM
    Pharmacogenomics J; 2019 Aug; 19(4):368-374. PubMed ID: 30647443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
    Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6 Receptor (IL6-R) Gene Polymorphisms Underlie Susceptibility to Rheumatoid Arthritis.
    Ahmed S; Hussain S; Ammar A; Jahan S; Khaliq S; Kaul H
    Clin Lab; 2017 Sep; 63(9):1365-1369. PubMed ID: 28879718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between the interleukin-6 rs1800795 G/C and interleukin-6 receptor rs12083537 A/G polymorphisms and response to disease-modifying antirheumatic drugs in rheumatoid arthritis: A meta-analysis.
    Lee YH; Song GG
    Int Immunopharmacol; 2022 Nov; 112():109184. PubMed ID: 36058033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
    Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
    Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Janahiraman S; Too CL; Lee KW; Shahril NS; Leong CO
    Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab.
    Lin N; Damask A; Boyapati A; Hamilton JD; Hamon S; Ternes N; Nivens MC; Penn J; Lopez A; Reid JG; Overton J; Shuldiner AR; Abecasis G; Baras A; Paulding C
    Pharmacogenomics J; 2022 May; 22(3):160-165. PubMed ID: 35149777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
    RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
    Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
    Burmester GR; Bykerk VP; Buch MH; Tanaka Y; Kameda H; Praestgaard A; van Hoogstraten H; Fernandez-Nebro A; Huizinga T
    Rheumatology (Oxford); 2022 May; 61(6):2596-2602. PubMed ID: 34508594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.